PCN reports : psychiatry and clinical neurosciences · 2025
Impact of antipsychotics, antiparkinsonian drugs, and anthraquinone stimulant laxatives on severe constipation in patients with schizophrenia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nadaya Toshiaki, Inaguma Tokuya, Nagao Tomoko, Ishida Takuto
Аннотация
AIM: Constipation in schizophrenia patients receiving antipsychotics can lead to severe intestinal complications, such as paralytic ileus or megacolon. Despite the clinical importance of the topic, few studies have thoroughly investigated the risk factors of constipation-related complications. Therefore, the present study aimed to identify clinical and pharmacological factors associated with severe, constipation-related conditions in patients with schizophrenia.
METHODS: The present, retrospective study analyzed inpatients with schizophrenia and constipation at Tokyo Metropolitan Matsuzawa Hospital between 2014 and 2018. Logistic regression analysis was performed to test for any association between severe, constipation-related conditions and patient demographics and the use of various antipsychotics, antiparkinsonian drugs, and anthraquinone stimulant laxatives.
RESULTS: Of the 4114 patients included, 556 had a severe, constipation-related condition. High dosages of clozapine (odds ratio [OR]: 8.688; 95% confidence interval [CI]: 1.926-39.186; p = 0.005), haloperidol (OR: 1.987; 95% CI: 1.093-3.610; p = 0.024), anthraquinone stimulant laxatives (OR: 1.769; 95% CI: 1.337-2.340; p < 0.001), antiparkinsonian drugs (OR: 1.641; 95% CI: 1.280-2.104; p < 0.001), and female sex (OR: 1.318; 95% CI: 1.097-1.582; p = 0.003) were found to be significantly associated with this condition. On the other hand, high-dosage risperidone was associated with a reduced risk (OR: 0.688; 95% CI: 0.508-0.932; p = 0.016).
CONCLUSION: These findings highlighted the need for careful monitoring of constipation and for optimizing antipsychotic drug regimens. The use of antiparkinsonian drugs and anthraquinone stimulant laxatives should be limited to the short term.
METHODS: The present, retrospective study analyzed inpatients with schizophrenia and constipation at Tokyo Metropolitan Matsuzawa Hospital between 2014 and 2018. Logistic regression analysis was performed to test for any association between severe, constipation-related conditions and patient demographics and the use of various antipsychotics, antiparkinsonian drugs, and anthraquinone stimulant laxatives.
RESULTS: Of the 4114 patients included, 556 had a severe, constipation-related condition. High dosages of clozapine (odds ratio [OR]: 8.688; 95% confidence interval [CI]: 1.926-39.186; p = 0.005), haloperidol (OR: 1.987; 95% CI: 1.093-3.610; p = 0.024), anthraquinone stimulant laxatives (OR: 1.769; 95% CI: 1.337-2.340; p < 0.001), antiparkinsonian drugs (OR: 1.641; 95% CI: 1.280-2.104; p < 0.001), and female sex (OR: 1.318; 95% CI: 1.097-1.582; p = 0.003) were found to be significantly associated with this condition. On the other hand, high-dosage risperidone was associated with a reduced risk (OR: 0.688; 95% CI: 0.508-0.932; p = 0.016).
CONCLUSION: These findings highlighted the need for careful monitoring of constipation and for optimizing antipsychotic drug regimens. The use of antiparkinsonian drugs and anthraquinone stimulant laxatives should be limited to the short term.